Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow. Latest Ratings for INCY DateFirmActio.....»»
Skyhawk’s latest biopharma collaboration is worth up to $1.8B
Skyhawk has also previously unveiled partnerships with the likes of Vertex Pharmaceuticals Inc., Bristol Myers Squibb, Takeda Pharmaceuticals, Genentech and Biogen Inc......»»
EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent
Adial Pharmaceuticals' genetic diagnostic patent, expanding treatment for alcohol and drug dependencies. CEO highlights the significance. read more.....»»
Marinus Pharmaceuticals loses 80% of its market value in one day after setback for new drug candidate
Marinus Pharmaceuticals said it will implement cost-cutting measures to extend its cash runway beyond the fourth quarter of 2024......»»
Why Bitcoin-Linked MicroStrategy Along With Adial Pharmaceuticals, Alpine Immune Sciences, Marin Software, And Tesla Are On Investors" Radars Today
On Wednesday, key U.S. stock indexes closed lower, as the Dow Jones I.....»»
Pieris stock rockets on record volume after Genentech collaboration valued at up to $1.4 billion
Shares of Pieris Pharmaceuticals Inc. rocketed 57.3% on massive volume in afternoon trading Tuesday, after the Boston-based biotechnology company announced a respiratory and ophthalmology collaboration with Roche Holding AG's .....»»
What"s Going On With Pieris Pharmaceuticals Stock Today?
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) shares are trading higher by 57% at $2.91 after the company announced a respiratory and ophthalmology collaboration with Genentech. read more.....»»
Oric Pharmaceuticals participates in a conference call with JPMorgan
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Amneal Pharmaceuticals management to meet virtually with Piper Sandler
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Universe Pharmaceuticals enters into LOI for cooperation with Kitanihon
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Oric Pharmaceuticals to host KOL call to review data on ORIC-101
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
: AstraZeneca’s $39 billion takeover of U.S.-based Alexion Pharmaceuticals examined by U.K. regulator
The deal has already been approved by the U.S. and Canadian authorities......»»
Anebulo Pharmaceuticals started at buy with $15 stock price target at Benchmark
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»
Xeris Pharmaceuticals price target lowered to $9 from $14 at Mizuho
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Adamis Pharmaceuticals discloses NY grand jury subpoena, criminal investigation
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Anebulo Pharmaceuticals initiated with a Buy at Benchmark
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Adamis Pharmaceuticals options imply 16.0% move in share price post-earnings
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Centessa Pharmaceutical sets IPO terms, seeking valuation of up to $1.7 billion
Centessa Pharmaceuticals PLC has set terms for its initial public offering, as the U.K.-based biotechnology holding company s.....»»
Xeris Pharmaceuticals to acquire Strongbridge Biopharma for $267M in stock, CVRs
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»